The PLAC® Activity Test is a strong and independent risk factor

The FDA cleared PLAC Activity Test showed a strong association with CHD events* as compared to traditional risk factors even after adjusting for age, gender, race, diabetes and smoking status. Only complex clinical conditions such as diabetes and smoking status demonstrated greater hazard ratios for CHD events.
Effectiveness of the PLAC Activity Test has been demonstrated across multiple clinical trials and patient populations.
- The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events (Figure 1)
- A PLAC Activity Test result above 225 nmol/min/mL identifies patients at increased risk for CHD events across patient type and population (Figure 2)
- Absolute risk of CHD events is 2.1 times greater with a positive PLAC Test (Figure 2)


 | The PLAC® Activity Test incorporates a validated, easy-to-use cut point of 225 nmol/min/mL. |
HEALTHCARE PROFESSIONALS
he PLAC Activity Test provides physicians with additional prognostic information previously unavailable with traditional risk factors.
LEARN MORE »
LABORATORY PROFESSIONALS
The PLAC Activity Test offers enhanced cardiovascular risk assessment from your laboratory.
LEARN MORE »